Clinical Trials Pipeline
Track progress across therapeutic areas and timelines
| Category | Trial | Collaborator | Indications | Expected Completion | 2025 | 2026 | 2027 | Program Launch | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | ||||||
|
HEALTH LONGEVITY
|
${ trial.id }
|
${ trial.collaborator } | ${ trial.indications } | ${ trial.expectedCompletion } |
|
${ trial.programLaunch } | |||||||||||
|
${ trial.id }
|
${ trial.collaborator } | ${ trial.indications } | ${ trial.expectedCompletion } |
|
${ trial.programLaunch } | ||||||||||||
|
AUTOIMMUNE & INFLAMMATION
|
${ trial.id }
|
${ trial.collaborator } | ${ trial.indications } | ${ trial.expectedCompletion } |
|
${ trial.programLaunch } | |||||||||||
|
CANCER
|
${ trial.id }
|
${ trial.collaborator } | ${ trial.indications } | ${ trial.expectedCompletion } |
|
${ trial.programLaunch } | |||||||||||
Study completed, paper in submission
Study completed, paper in
preparation
Planned/Future
Pipeline Overview
Drug development programs across discovery to late-stage development
| Program | Target | Indications | Discovery | Pre-clinical development | Early development | Late development | Rights |
|---|---|---|---|---|---|---|---|
|
${ program.name
}
${ program.note }
|
${ program.target } | ${ program.indications } |
|
|
1 License and collaboration agreement with Betta Pharmaceuticals for development
and commercialization in Greater China
2 In May 2025, C4T announced CFT1946 will not advance beyond Phase I and that
the company will seek partnership for the BRAF program